{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:18:01Z","timestamp":1789834681320,"version":"4.0.1"},"reference-count":58,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.5551\/jat.rv17034","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T22:11:51Z","timestamp":1556575911000},"page":"583-591","source":"Crossref","is-referenced-by-count":52,"title":["Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease"],"prefix":"10.5551","volume":"26","author":[{"given":"Hayato","family":"Tada","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kanazawa University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masa-aki","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis, 2016; 245: 161-170","DOI":"10.1016\/j.atherosclerosis.2015.12.018"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Suwa S, Ogita M, Miyauchi K, Sonoda T, Konishi H, Tsuboi S, Wada H, Naito R, Dohi T, Kasai T, Okazaki S, Isoda K, Daida H. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. J Atheroscler Thromb, 2017; 24: 1125- 1131","DOI":"10.5551\/jat.38794"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol, 2013; 61: 1146-1156","DOI":"10.1016\/j.jacc.2012.12.023"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009; 361: 2518-2528","DOI":"10.1056\/NEJMoa0902604"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, Stirrups K, K\u00f6nig IR, Cazier JB, Johansson A, Hall AS, Lee JY, Willer CJ, Chambers JC, Esko T, Folkersen L, Goel A, Grundberg E, Havulinna AS, Ho WK, Hopewell JC, Eriksson N, Kleber ME, Kristiansson K, Lundmark P, Lyytik\u00e4inen LP, Rafelt S, Shungin D, Strawbridge RJ, Thorleifsson G, Tikkanen E, Van Zuydam N, Voight BF, Waite LL, Zhang W, Ziegler A, Absher D, Altshuler D, Balmforth AJ, Barroso I, Braund PS, Burgdorf C, ClaudiBoehm S, Cox D, Dimitriou M, Do R; DIAGRAM Consortium; CARDIOGENICS Consortium, Doney AS, El Mokhtari N, Eriksson P, Fischer K, Fontanillas P, FrancoCereceda A, Gigante B, Groop L, Gustafsson S, Hager J, Hallmans G, Han BG, Hunt SE, Kang HM, Illig T, Kessler T, Knowles JW, Kolovou G, Kuusisto J, Langenberg C, Langford C, Leander K, Lokki ML, Lundmark A, McCarthy MI, Meisinger C, Melander O, Mihailov E, Maouche S, Morris AD, M\u00fcller-Nurasyid M; MuTHER Consortium, Nikus K, Peden JF, Rayner NW, Rasheed A, Rosinger S, Rubin D, Rumpf MP, Sch\u00e4fer A, Sivananthan M, Song C, Stewart AF, Tan ST, Thorgeirsson G, van der Schoot CE, Wagner PJ; Wellcome Trust Case Control Consortium, Wells GA, Wild PS, Yang TP, Amouyel P, Arveiler D, Basart H, Boehnke M, Boerwinkle E, Brambilla P, Cambien F, Cupples AL, de Faire U, Dehghan A, Diemert P, Epstein SE, Evans A, Ferrario MM, Ferri\u00e8res J, Gauguier D, Go AS, Goodall AH, Gudnason V, Hazen SL, Holm H, Iribarren C, Jang Y, K\u00e4h\u00f6nen M, Kee F, Kim HS, Klopp N, Koenig W, Kratzer W, Kuulasmaa K, Laakso M, Laaksonen R, Lee JY, Lind L, Ouwehand WH, Parish S, Park JE, Pedersen NL, Peters A, Quertermous T, Rader DJ, Salomaa V, Schadt E, Shah SH, Sinisalo J, Stark K, Stefansson K, Tr\u00e9gou\u00ebt DA, Virtamo J, Wallentin L, Wareham N, Zimmermann ME, Nieminen MS, Hengstenberg C, Sandhu MS, Pastinen T, Syv\u00e4nen AC, Hovingh GK, Dedoussis G, Franks PW, Lehtim\u00e4ki T, Metspalu A, Zalloua PA, Siegbahn A, Schreiber S, Ripatti S, Blankenberg SS, Perola M, Clarke R, Boehm BO, O\u2019Donnell C, Reilly MP, M\u00e4rz W, Collins R, Kathiresan S, Hamsten A, Kooner JS, Thorsteinsdottir U, Danesh J, Palmer CN, Roberts R, Watkins H, Schunkert H, Samani NJ. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet, 2013; 45: 25-33","DOI":"10.1038\/ng.2480"},{"key":"7","unstructured":"7) Owens DS, O\u2019Brien KD. Clinical and genetic risk factors for calcific valve disease. In: Otto CM, Bonow RO, eds. Valvular Heart Disease. A Companion to Branwald\u2019s Heart Diseqase. 4th ed. Philadelphia: Elsevier-Saunders; 2013: 53-62"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Boss\u00e9 Y, Mathieu P, Pibarot P. Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol, 2008; 51: 1327-1336","DOI":"10.1016\/j.jacc.2007.12.031"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Rogers MA, Aikawa E. A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease. Circulation, 2015; 132: 621-623","DOI":"10.1161\/CIRCULATIONAHA.115.018139"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Capoulade R, Chan KL, Yeang C, Mathieu P, Boss\u00e9 Y, Dumesnil JG, Tam JW, Teo KK, Mahmut A, Yang X, Witztum JL, Arsenault BJ, Despr\u00e9s JP, Pibarot P, Tsimikas S. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol, 2015; 66: 1236-1246","DOI":"10.1016\/j.jacc.2015.07.020"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Fless GM, ZumMallen ME, Scanu AM. Isolation of apolipoprotein(a) from lipoprotein(a). J Lipid Res, 1985; 26: 1224-1229","DOI":"10.1016\/S0022-2275(20)34270-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature, 1987; 330: 132-137","DOI":"10.1038\/330132a0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol, 2017; 69: 692-711","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tada H, Kawashiri MA, Yoshida T, Teramoto R, Nohara A, Konno T, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. Circ J, 2016; 80: 512-518","DOI":"10.1253\/circj.CJ-15-0999"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest, 1992; 90: 52-60","DOI":"10.1172\/JCI115855"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lin J, Reilly MP, Terembula K, Wilson FP. Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One, 2014; 9: e114397","DOI":"10.1371\/journal.pone.0114397"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Langsted A, Kamstrup PR, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol, 2016; 4: 577-587","DOI":"10.1016\/S2213-8587(16)30042-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest, 1980; 65: 1483-1490","DOI":"10.1172\/JCI109813"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest, 1993; 91: 443-447","DOI":"10.1172\/JCI116221"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G.Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest, 1989; 83: 137-142","DOI":"10.1172\/JCI113849"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem, 1994; 269: 28716-2823","DOI":"10.1016\/S0021-9258(19)61964-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hrzenjak A, Frank S, Wo X, Zhou Y, Van Berkel T, Kostner GM. Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism. Biochem J, 2003; 376: 765-771","DOI":"10.1042\/bj20030932"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res, 2005; 46: 2681-2691","DOI":"10.1194\/jlr.M500249-JLR200"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest, 1994; 93: 2758-2763","DOI":"10.1172\/JCI117292"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest, 1995; 95: 1403-1408","DOI":"10.1172\/JCI117794"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest, 1989; 19: 235-240","DOI":"10.1111\/j.1365-2362.1989.tb00223.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, Couderc R, Dati F, Rifai N, Sakurabayashi I, Tate JR, Steinmetz A. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem, 2000; 46: 1956-1967","DOI":"10.1093\/clinchem\/46.12.1956"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thromboly sis.Nat Med, 1995; 1: 256-259","DOI":"10.1038\/nm0395-256"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res, 1990; 57: 155-162","DOI":"10.1016\/0049-3848(90)90203-O"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Edelberg JM, Reilly CF, Pizzo SV. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). J Biol Chem, 1991; 266: 7488-7493","DOI":"10.1016\/S0021-9258(20)89472-1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation, 1997; 96: 2514-2519","DOI":"10.1161\/01.CIR.96.8.2514"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol, 1991; 113: 1439-1445","DOI":"10.1083\/jcb.113.6.1439"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature, 1994; 370: 460-462","DOI":"10.1038\/370460a0"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Yano Y, Seishima M, Tokoro Y, Noma A. Stimulatory effects of lipoprotein(a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2. Biochim Biophys Acta, 1998; 1393: 26-34","DOI":"10.1016\/S0005-2760(98)00052-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Morishita R, Yamamoto K, Yamada S, Matsushita H, Tomita N, Sakurabayashi I, Kaneda Y, Moriguchi A, Higaki J, Ogihara T. Stimulatory effect of lipoprotein (a) on proliferation of human mesangial cells: role of lipoprotein (a) in renal disease. Biochem Biophys Res Commun, 1998; 249: 313-320","DOI":"10.1006\/bbrc.1998.9116"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Takami S, Yamashita S, Kihara S, Ishigami M, Takemura K, Kume N, Kita T, Matsuzawa Y. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation, 1998; 97: 721-728","DOI":"10.1161\/01.CIR.97.8.721"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Allen S, Khan S, Tam Sp, Koschinsky M, Taylor P, Yacoub M.Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. FASEB J, 1998; 12: 1765-1776","DOI":"10.1096\/fasebj.12.15.1765"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common dis eases and 3,000 shared controls. Nature, 2007; 447: 661- 678","DOI":"10.1038\/nature05911"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009; 361: 2518-2528","DOI":"10.1056\/NEJMoa0902604"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O\u2019Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, K\u00e4lsch H, M\u00fchleisen TW, N\u00f6then MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O\u2019Donnell CJ, Post WS; CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med, 2013; 368: 503-512","DOI":"10.1056\/NEJMoa1109034"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Tada H, Kawashiri MA, Yamagishi M. Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. J Atheroscler Thromb, 2017; 24: 452-61","DOI":"10.5551\/jat.RV17002"},{"key":"42","unstructured":"42) Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, K\u00f6nig I, Asselta R, Merlini PA, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O\u2019Donnell CJ, Abecasis G, Sunaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S. N Engl J Med, 2014; 371: 2072-2082"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Nomura A, Won HH, Khera AV, Takeuchi F, Ito K, McCarthy S, Emdin CA, Klarin D, Natarajan P, Zekavat SM, Gupta N, Peloso GM, Borecki IB, Teslovich TM, Asselta R, Duga S, Merlini PA, Correa A, Kessler T, Wilson JG, Bown MJ, Hall AS, Braund PS, Carey DJ, Murray MF, Kirchner HL, Leader JB, Lavage DR, Manus JN, Hartze DN, Samani NJ, Schunkert H, Marrugat J, Elosua R, McPherson R, Farrall M, Watkins H, Juang JJ, Hsiung CA, Lin SY, Wang JS, Tada H, Kawashiri MA, Inazu A, Yamagishi M, Katsuya T, Nakashima E, Nakatochi M, Yamamoto K, Yokota M, Momozawa Y, Rotter JI, Lander ES, Rader DJ, Danesh J, Ardissino D, Gabriel S, Willer CJ, Abecasis GR, Saleheen D, Kubo M, Kato N, Ida Chen YD, Dewey FE, Kathiresan S. Circ Res, 2017; 121: 81-88","DOI":"10.1161\/CIRCRESAHA.117.311145"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen YI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dub\u00e9 MP, Ebeling T, Eiriksdottir G, Esko T, Farmaki AE, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin MR, Jensen GB, J\u00f8rgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJF, Lu Y, Lu X, M\u00e4gi R, Malarstig A, Manichaikul A, Manning AK, M\u00e4ntyselk\u00e4 P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, M\u00fcller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O\u2019Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renstr\u00f6m F, Rich SS, Ridker PM, Rioux JD, Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, Stirrups KE, Stitziel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, Tardif JC, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam NR, Varbo A, Varga TV, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, Weeke PE, Weinstock J, Wessel J, Wilson JG, Wilson PWF, Xu M, Yaghootkar H, Young R, Zeggini E, Zhang H, Zheng NS, Zhang W, Zhang Y, Zhou W, Zhou Y, Zoledziewska M; Charge Diabetes Working Group; EPIC-InterAct Consortium; EPIC-CVD Consortium; GOLD Consortium; VA Million Veteran Program, Howson JMM, Danesh J, McCarthy MI, Cowan CA, Abecasis G, Deloukas P, Musunuru K, Willer CJ, Kathiresan S. Nat Genet, 2017; 49: 1758-1766","DOI":"10.1038\/ng.3977"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, Stitziel NO, Nomura A, Zekavat SM, Bick AG, Gupta N, Asselta R, Duga S, Merlini PA, Correa A, Kessler T, Wilson JG, Bown MJ, Hall AS, Braund PS, Samani NJ, Schunkert H, Marrugat J, Elosua R, McPherson R, Farrall M, Watkins H, Willer C, Abecasis GR, Felix JF, Vasan RS, Lander E, Rader DJ, Danesh J, Ardissino D, Gabriel S, Saleheen D, Kathiresan S; CHARGEHeart Failure Consortium; CARDIoGRAM Exome Consortium. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol, 2016; 68: 2761-2772","DOI":"10.1016\/j.jacc.2016.10.033"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Rosseb\u00f8 AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-B\u00e4rwolf C, Holme I, Kes\u00e4niemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med, 2008; 359: 1343-1356","DOI":"10.1056\/NEJMoa0804602"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Capoulade R, Chan KL, Yeang C, Mathieu P, Boss\u00e9 Y, Dumesnil JG, Tam JW, Teo KK, Mahmut A, Yang X, Witztum JL, Arsenault BJ, Despr\u00e9s JP, Pibarot P, Tsimikas S. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol, 2015; 66: 1236-1246","DOI":"10.1016\/j.jacc.2015.07.020"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol, 2015; 65: 2267-2275","DOI":"10.1016\/j.jacc.2015.03.544"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Tada H, Kawashiri MA, Nomura A, Yoshimura K, Itoh H, Komuro I, Yamagishi M. Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy. Eur J Prev Cardiol, 2018; 25: 1852-1860","DOI":"10.1177\/2047487318796989"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Albers JJ, Slee A, O\u2019Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol, 2013; 62: 1575-1579","DOI":"10.1016\/j.jacc.2013.06.051"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation, 2014; 129: 635-642","DOI":"10.1161\/CIRCULATIONAHA.113.004406"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Fieseler HG, Armstrong VW, Wieland E, Thiery J, Sch\u00fctz E, Walli AK, Seidel D. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation. Clin Chim Acta, 1991; 204: 291-300","DOI":"10.1016\/0009-8981(91)90239-9"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Awad K, Mikhailidis DP2, Katsiki N3, Muntner P4, Banach M5,6,7; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs, 2018; 78: 453-62","DOI":"10.1007\/s40265-018-0870-1"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Ginsberg HN, Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol, 2014; 114: 711-715","DOI":"10.1016\/j.amjcard.2014.05.060"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J, 2018; 39: 2577-2585","DOI":"10.1093\/eurheartj\/ehy122"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation, 2017; 135: 352-362","DOI":"10.1161\/CIRCULATIONAHA.116.025253"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Nandakumar R, Matveyenko A, Thomas T, Pavlyha M, Ngai C, Holleran S, Ramakrishnan R, Ginsberg HN, Karmally W, Marcovina SM, Reyes-Soffer G. Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. J Lipid Res, 2018; 59: 2397-2402","DOI":"10.1194\/jlr.P082834"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Tsimikas S. Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. Circ Res, 2019; 124: 405-415","DOI":"10.1161\/CIRCRESAHA.118.313864"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/7\/26_RV17034\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T03:26:40Z","timestamp":1663385200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/7\/26_RV17034\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17034","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}